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Abstract
Designing subtype-selective agonists for neuronal nicotinic acetylcholine receptors is a 
challenging and significant goal aided by intricate knowledge of each subtype’s binding patterns. 
We previously reported that in α6β2 receptors, acetylcholine makes a functional cation-π 
interaction with Trp149, but nicotine and TC299423 do not, suggesting a distinctive binding site. 
This work explores hydrogen binding at the backbone carbonyl associated with α6β2 Trp149. 
Substituting residue i + 1, Thr150, with its α-hydroxy analogue (Tah) attenuates the carbonyl’s 
hydrogen bond accepting ability. At α6(T150Tah)β2, nicotine shows a 24-fold loss of function, 
TC299423 shows a modest loss, and acetylcholine shows no effect. Nicotine was further analyzed 
via a double-mutant cycle analysis utilizing N’- methylnicotinium, which indicated a hydrogen 
bond in α6β2 with a ΔΔG of 2.6 kcal/mol. Thus, even though nicotine does not make the 
conserved cation- π interaction with Trp149, it still makes a functional hydrogen bond to its 
associated backbone carbonyl.
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The neuronal nicotinic acetylcholine receptors (nAChRs) make up a group of pentameric 
ligand-gated ion channels (pLGICs) typically found at presynaptic terminals, where they 
modulate neurotransmitter release.1–3 There are 11 known subunits (α2-α7, α9, α10, and 
β2-β4) that assemble into pentamers in different combinations.4 The different subunits share 
a common topology, and the agonist binding site is found in the extracellular binding region 
at the interface of two subunits. Different subunit combinations, i.e., different nAChR 
subtypes, display distinctive functions, pharmacologies, and localizations.5 While several 
subtypes are distributed throughout the brain (e.g., α4β2 and α7), others are concentrated in 
specific regions and expressed by only certain cell types.6,7 The α6-containing subtypes 
follow the latter pattern and are prominently expressed in dopaminergic neurons of the 
ventral tegmental area and the substantia nigra pars compacta, making them promising 
targets for both Parkinson’s disease and addiction.8–10 In addition, the α6 subunit is 
expressed in dorsal root ganglia, where it plays an important role in mechanical allodynia 
associated with neuropathies and inflammatory injuries.11 As such, insights into strategies 
for targeting drugs specifically to α6-containing nAChRs would be quite valuable.
Mapping the binding interface is a major step toward that goal. A growing collection of 
structural data has provided valuable guidance, but it has been less helpful in revealing the 
subtle features that distinguish particular subtypes. For prototype agonists such as ACh and 
nicotine (structures shown in Figure 1A), the residues comprising the primary and 
complementary binding interfaces are conserved among all α and all β subunits, 
respectively.12 Therefore, additional precision is required to understand the functional details 
of neuronal nAChR binding sites.13 We have established a strategy based on the 
incorporation of noncanonical amino acids and electrophysiological characterization that 
allows high-precision characterization of drug-receptor interactions in nAChRs and related 
systems.14 Application of this approach to the α4β2 nAChR, the most common nicotinic 
receptor in the brain, revealed three key binding interactions: a cation-πinteraction with α4 
Trp149, a hydrogen bond with the backbone carbonyl associated with Trp149, and an 
additional hydrogen bond between nicotine’s pyridine nitrogen and a backbone NH in the β2 
subunit.15,16 The cation-π interaction at Trp149, which is also termed TrpB as it lies on 
canonical “loop B” of the primary agonist binding site, has been observed at homologous 
aromatic residues throughout the nAChR and broader pLGIC families and was later 
corroborated in recent crystal structures of α4β2 nAChR, glycine, and serotonin receptors.
17–21
 However, recent work using noncanonical amino acid mutagenesis has shown that in 
the α6β2 receptor, acetylcholine makes a functionally important cation-π interaction, but 
nicotine and TC299423 [an agonist that shows some selectivity for α6β2 receptors22 
(structure shown in Figure 1A)] do not.23 This binding mode differs from that of the α4β2 
subtype, which suggests the question of what interactions besides a cation-π interaction at 
Trp149 might be responsible for the binding of nicotine and TC299423 in the α6β2 nAChR.
This report investigates the role of a possible hydrogen bond between an agonist’s amine 
moiety and the backbone carbonyl associated with TrpB in α6β2. While quaternary 
ammonium agonists such as acetylcholine cannot make a hydrogen bond, such interactions 
have been observed in α4β2 for nicotine and the smoking cessation drugs varenicline 
(Chantix) and cytisine (Tabex),24,25 all of which contain a protonated amine (ammonium 
ion) that provides the hydrogen bond donor. In each of those instances, evidence of the 
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hydrogen bond was accompanied by evidence of a cation—π interaction at TrpB; however, 
because nicotine was not observed to make a strong cation—π interaction at TrpB with 
α6β2, it was uncertain whether it would make the corresponding hydrogen bond with that 
tryptophan’s backbone carbonyl. Here, structure—function studies using α-hydroxy acid 
substitution reveal that nicotine indeed makes a functional hydrogen bond with this 
backbone carbonyl in α6β2. The interaction is further supported and quantified by a double-
mutant cycle analysis utilizing N’- methylnicotinium. In contrast, TC299423 shows at best a 
weak interaction with this carbonyl
RESULTS AND DISCUSSION
α-Hydroxy Acid Substitution at Thr150 in α6β2‡.
All studies make use of the previously described α6β2‡ construct, which contains mutations 
far removed from the agonist binding site that increase plasma membrane levels, in part, by 
facilitating transport from the endoplasmic reticulum to the cell surface.23 To probe for a 
hydrogen bond to a backbone carbonyl, residue i + 1 is mutated to the corresponding α-
hydroxy acid (Figure 1B).26 In both α6β2‡ and α4β2, residue i + 1 to Trp149 is Thr150. In 
the mutation to threonine α-hydroxy acid (Tah), the amide backbone becomes an ester 
backbone without affecting the side chain (Figure 1C). It is well established that an ester 
carbonyl is a significantly weaker hydrogen bond acceptor than an amide carbonyl is.27 In 
previous studies of several nAChR subtypes, this mutation has produced shifts in EC50 
ranging from 3- to 27-fold.13
The results of substituting α6 Thr150 with Tah are summarized in Table 1. Importantly, 
ACh, which cannot make a conventional hydrogen bond to the backbone carbonyl, shows no 
significant effect. This establishes that the function of the receptor has not been degraded in 
some generic fashion by the backbone mutation. In sharp contrast, nicotine displays a 24-
fold increase in EC50 (loss of function, dose responses shown in Figure 1D), suggesting it 
makes a potent hydrogen bond with the backbone carbonyl of TrpB. Perhaps surprisingly, 
only a 4-fold loss of function was observed for TC299423.
Quantifying the α6β2*—Nicotine Hydrogen Bond.
Our results show that perturbing the backbone carbonyl at TrpB strongly impacts nicotine 
activation of the α6β2‡ receptor. This is highly suggestive of a hydrogen bond, but other 
explanations are possible. Also, putting an energetic value on the proposed hydrogen bond is 
challenging. A classic technique in determining a functional coupling interaction between 
amino acids in a protein is double-mutant cycle analysis.28–30 In this type of experiment, the 
two amino acids of interest are each mutated in a way that would attenuate the proposed 
interaction, both independently (as single mutants) and simultaneously (as a double mutant). 
If the change in binding seen in the double mutant is a simple sum of each single mutant—
that is, if the energetic effects are additive—the single-mutant perturbations act 
independently of each other, and the two amino acids do not participate in a functionally 
coupled interaction. If, on the other hand, the effect of the double mutant proves to be 
nonadditive, the amino acids are considered to be functionally coupled. The degree to which 
the double mutant is additive or nonadditive is expressed by an Ω value, which is defined as 
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the product of the wild-type and double-mutant EC50 values divided by the product of the 
single-mutant EC50 values (Figure 2). An Ω value differing from 1 indicates functional 
coupling between amino acids. As discussed elsewhere, perturbations to EC50 resulting from 
mutations at the agonist binding site can be considered to reflect changes in agonist binding 
affinities, allowing an Ω valueto be converted to a ΔΔΟ for the coupling energy between 
amino acids.29,31–33
To assess the nicotine hydrogen bond with the TrpB backbone carbonyl, we designed an 
analogue of double-mutant cycle analysis (schematic shown in Figure 2). The first mutant in 
the analysis is the T150Tah substitution that results in an amide-to-ester backbone mutation. 
The second “mutant” uses a nicotine analogue, wherein the pyrrolidine nitrogen is 
methylated to yield N’-methylnicotinium (N’MeNic in data tables). As a quaternary 
ammonium, this compound is similar to ACh in that it cannot donate a hydrogen bond. By 
determining EC50 values for each condition (nicotine at the wild type, nicotine at T150Tah, 
N’-methylnicotinium at the wild type, and N’-methylnicotinium at T150Tah) and 
determining whether the double mutant shows an additive loss of function, this mutant cycle 
will not only further test the hypothesis that nicotine makes a hydrogen bond with the 
backbone carbonyl of Trp149 but also quantify the strength of the hydrogen bond. We have 
previously used a similar mutant cycle analysis, one mutation being on the protein the other 
on the drug, to probe the hydrogen bond involving the pyridine N of nicotine.30
As a proof of concept, the double-mutant cycle analysis described above was first performed 
in the α4β2 nAChR, because this subtype is more extensively studied and has a better 
understood binding map for nicotine. At α4β2, nicotine shows a 27-fold shift in EC50 at the 
T150Tah mutant, a major loss of function (Table 2). When N’-methylnicotinium is tested at 
the wild-type receptor, a 6-fold loss of function is observed. If these two mutations were 
independent of each other, meaning loss of function was due to an effect other than 
attenuating the proposed hydrogen bond, an additive loss of function would be expected at 
the double mutant close to 160-fold. Instead, an EC50 of 0.40 μM is observed, which is not 
meaningfully different from the EC50 of N’-methylnicotinium at the wild type (0.62 μM) 
and only a 4-fold loss of function compared to nicotine at the wild type. This lack of 
additivity is quantified with an Ω value of 42, which when expressed in free energy terms 
reveals a ΔΔG value of −2.2 kcal/mol. This value is comparable to empirically determined 
hydrogen bond strengths of N-methylacetamide aggregates in carbon tetrachloride (ΔΗ° = 
−4.2 kcal/mol) and benzene (ΔΗ° = −3.6 kcal/mol).34,35
The same approach was taken in α6β2*; as noted above, nicotine experiences a 24-fold loss 
of function at T150Tah. The other single mutant in this analysis, which is N’-methylnico-
tinium at wild-type α6β2‡, shows an even larger loss of function, with a 38-fold shift in 
EC50. If these losses in function were not due to hydrogen bonding and instead were 
independent of each other, the double-mutant fold shift would be additive with a nearly 900-
fold increase in EC50 with respect to that of the wild type. The double mutant, N’- 
methylnicotinium at T150Tah, has instead an EC50 of 1.2, μM, an 11-fold shift away from 
that of the wild type, showing the effect is nonadditive. Overall, the mutant cycle has an Ω 
value of 88 and a ΔΔG of −2.6 kcal/mol, suggesting nicotine makes a hydrogen bond in 
α6β2* that is at least as strong as that seen in α4β2.
Post et al. Page 4
Biochemistry. Author manuscript; available in PMC 2018 August 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CONCLUSION
These results reveal an interesting diversity among nAChR subtypes. First, consider the 
binding of nicotine at the two different receptor subtypes, α4β2 and α6β2. The binding 
pattern for α4β2 is familiar, a strong cation—π interaction with TrpB and a strong hydrogen 
bond to the associated backbone carbonyl. In α6β2, the cation—π interaction is absent, so 
one might conclude that the drug had moved away from TrpB. We now find that nicotine 
makes a comparably strong hydrogen bond to the backbone carbonyl in α6β2, a surprising 
and intriguing binding pattern. Another interesting difference is seen in the consequences of 
quaternizing nicotine, making it more like the natural agonist ACh. In α4β2, this has a 
modest effect on potency (an only 6-fold shift), but in α6β2, the impact is markedly larger (a 
37-fold shift), again suggesting an altered binding orientation.
Finally, our results suggest that TC299423 interacts very weakly with TrpB. There is no 
evidence of a cation—π interaction, and a backbone mutation has an effect much smaller 
than that seen for nicotine. These findings should provide valuable guidance to efforts to 
develop subtype-specific drugs targeting α6-containing nAChRs.
MATERIALS AND METHODS
Molecular Biology.
Rat α6, α4, and β2 nAChRs were in the pGEMhe vector, a cDNA plasmid optimized for 
protein expression in Xenopus oocytes. Site-directed mutagenesis was performed by 
polymerase chain reaction using the Stratagene QuikChange protocol and primers ordered 
from Integrated DNA Technologies (Coralville, IA). Circular cDNA was linearized with 
SbfI (New England Biolabs, Ipswich, MA) and then transcribed in vitro using the T7 
mMessage mMachine kit (Life Technologies, Santa Clara, CA), with a purification step after 
each process (Qiagen, Valencia, CA). Final concentrations were quantified by ultraviolet 
spectroscopy.
Ion Channel Expression and α-Hydroxy Acid Incorporation.
For optimized expression, α4L9’Aβ2 and α6L9’Sβ2L9’SLFM/AAQA were used as the “wild-
type” receptor against which further mutations are compared. These are termed α4β2 and 
α6β2*, respectively, throughout for the sake of clarity. For nonsense suppression-based, site-
specific noncanonical amino acid incorporation, the cyanomethylester form of threonine α-
hydroxy was first synthesized, coupled to the dinucleotide dCA, and enzymatically ligated to 
UAG suppressor 74-mer THG73 tRNACUA as previously described.13 The product was 
verified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry on a 
3-hydrox- ypicolinic acid matrix. Xenopus laevis oocytes (stage V—VI) were sourced from 
both a Caltech facility and Ecocyte Bio Science (Austin, TX). The Tah-tRNA was injected 
along with T150UAG mRNA into oocytes in a 1:1 volume ratio, with an α6:β2 mRNA mass 
ratio of 10:1 or an α4:β2 mass ratio of 1:3, resulting in 25 ng each of mRNA and tRNA 
injected per cell. Cells were incubated for 24—48 h at 18 °C in an ND96 solution [96 mM 
NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES (pH 7.5)] enriched with theophylline, 
sodium pyruvate, gentamycin, and horse serum. The fidelity of incorporation of Tah was 
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confirmed by charging tRNA with Thr in a wild-type recovery experiment. Data from these 
experiments (reported as Thr in Tables 1 and 2) matched wildtype data, reported in previous 
studies. A read-through/re-aminoacylation test serves as a negative control wherein a 76- 
mer tRNA is injected alongside mRNA. A lack of current proved there was no detectable re-
aminoacylation at the Thr150 site.
N’-Methylnicotinium Synthesis.
Synthesis of N’-methyl- nicotinium was based on previously reported methods.36 All 
reagents were purchased from Sigma-Aldrich (St. Louis, MO). In a round-bottom flask, 19.8 
mL of (—)-nicotine was added to 250 mL of acetonitrile and excess sodium carbonate. 
Then, 5.76 mL of methyl iodide was added dropwise while the mixture was being stirred. 
The reaction mixture was stirred at room temperature for 3 days. The reaction solution was 
filtered by vacuum, and solids were discarded. Solvent from the filtrate was removed by 
rotary evaporation until a tan oil remained. Deionized water (50 mL) was added to the oil 
and dissolved, forming an orange solution. Continuous chloroform extraction was performed 
on the orange solution for 5 days. The aqueous layer was isolated, and solvent was removed 
by rotary evaporation upon which crystals formed. The product was recrystallized three 
consecutive times with hot isopropanol for a yield of >40%. Further purification was 
achieved by iterative preparative high-performance liquid chromatography (Waters, Milford, 
MA) using a 100% water solvent profile: 1H NMR (500 MHz, acetonitrile-d3) δ 8.80 (dd, J 
= 2.5, 0.8 Hz, 1H), 8.71 (dd, J = 4.8, 1.6 Hz, 1H), 8.12—8.00 (m, 1H), 7.50 (ddd, J = 8.0, 
4.8, 0.9 Hz, 1H), 5.06 (dd, J = 11.5, 8.0 Hz, 1H), 3.95— 3.69 (m, 2H), 3.12 (s, 3H), 2.75 (s, 
3H), 2.74—2.63 (m, 1H), 2.57—2.42 (m, 1H), 2.39—2.19 (m, 2H).
Whole-Cell Electrophysiological Characterization.
Acetylcholine chloride and (—)-nicotine tartrate were purchased from Sigma-Aldrich, while 
TC299423 (Targacept) was a generous gift. N’-Methylnicotinium iodide was prepared 
according to the procedure described above. Agonist-induced currents were recorded in two-
electrode voltage-clamp mode using the OpusXpress 6000A instrument (Molecular Devices, 
Sunnyvale, CA) at a holding potential of —60 mV in a running buffer of Ca2+-free ND96. 
Agonists were prepared in Ca2+-free ND96 and delivered to cells via a 1 mL application 
over 15 s followed by a 2 min wash. EC50 values describe the concentration required to 
activate half the receptors expressed on the cell surface and were determined through dose—
response experiments, while fold shifts in EC50 are equal to the mutant EC50 divided by the 
wild-type EC50. To derive an EC50 value, data from dose—response experiments were 
normalized to the maximal current response, averaged, and fit to the Hill equation using 
Kaleidagraph (Synergy Software, Reading, PA), though data are visualized here with Prism 
(GraphPad Software, La Jolla, CA). Error bars, as well as reported errors for EC50 and the 
Hill coefficient (nH), are presented as standard errors of the mean.
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Figure 1. 
(A) Agonists used to probe for hydrogen bonds with the Trp149-associated backbone 
carbonyl in α6β2. (B and C) Probing H- bonds uses the Tah strategy, which effectively 
mutates the amide backbone into an ester bond. (D) A functional hydrogen bond results in 
an increase in EC50 in the Tah mutant (pink dose-response curve) relative to that of the wild 
type (blue).
Post et al. Page 9
Biochemistry. Author manuscript; available in PMC 2018 August 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Schematic of the double-mutant cycle analysis used to confirm and quantify a functional 
hydrogen bond between nicotine at α6β2 receptors. Equations used to calculate Ω and ΔΔG 
values are shown.
Post et al. Page 10
Biochemistry. Author manuscript; available in PMC 2018 August 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Post et al. Page 11
Table 1.
Hydrogen Bonding at the α6β2* TrpB Carbonyl
EC50 (μM) nH Imax (μA) x-fold shift N
Ach
Thr 0.16 ± 0.01 1.3 ± 0.1 0.32—3.8 10
Tah 0.20 ± 0.01 0.9 ± 0.1 0.48—3.3 1.3 10
Nicotine
Thr 0.11 ± 0.01 1.4 ± 0.1 0.19—2.7 16
Tah 2.7 ± 0.1 1.2 ± 0.1 0.09—2.7 24 10
TC299423
Thr 0.08 ± 0.01 1.1 ± 0.1 0.21—3.6 11
Tah 0.30 ± 0.01 0.9 ± 0.1 0.12—4.1 3.8 13
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Table 2.
Double-Mutant Cycle Analysis of the Nicotine-TrpB Carbonyl Hydroge n Bond
agonist T150 EC50 (μM) nH Imax (μ A) x-fold shift N
α4β2
WT Nic Thr 0.10 ± 0.01 1.4 ± 0.2 0.05–1.2 1 15
Mut1 Nic Tah 2.7 ± 0.1 1.3 ± 0.1 0.11–1.2 27 6
Mut2 N’MeNic Thr 0.62 ± 0.03 1.2 ± 0.1 0.02–0.60 6.2 10
Mut1,2 N’MeNic Tah 0.40 ± 0.04 1.1 ± 0.1 0.08–0.42 4.0 12
Ω = 42
ΔΔG (kcal/mol) = −2.2
α6β2‡
WT Nic Thr 0.11 ± 0.01 1.4 ± 0.1 0.19–2.7 1 16
Mut1 Nic Tah 2.7 ± 0.1 1.1 ± 0.1 0.09–2.7 24 10
Mut2 N’MeNic Thr 4.2 ± 0.2 1.0 ± 0.1 0.10–2.1 38 11
Mut1,2 N’MeNic Tah 1.1 ± 0.1 0.9 ± 0.1 0.08–1.1 11 10
Ω = 88
ΔΔG (kcal/mol) = −2.6
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